Introduction Multiple myelomas are neoplasms of antibody-secreting, terminally differentiated plasma cells (B cells) that home to and expand in the bone marrow. In this, chromosome translocations frequently place oncogenes under the control of immunoglobulin enhancers. 1 It is the second most common type of blood cancer after the non-Hodgkin’s lymphoma. In 2019, the number of cases diagnosed with multiple myeloma is 1,59,985.
In the last 30 years, incident cases of myeloma increased by 126% globally and deaths due to it increased by 94%. 2 In the last 30 years, there is a worldwide increase in the myeloma cases by 126 % and the associated death rate is 94% . There are different therapeutic medications available for the management of multiple myeloma. Selinexor is the drug entity that was approved by the US FDA in 2019 with dexamethasone for the management of refractory/relapsed multiple…
